Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesThere is no single treatment for recurrent ovarian cancer. The main decision is whether the cancer returned more than six months after platinum chemotherapy, within six months, or progressed during treatment. For a later recurrence, a platinum-based combination is usually offered; for an early recurrence or progression during treatment, clinicians generally consider non-platinum options. Tumor type, prior medicines, biomarker results, symptoms, overall health, and personal preferences help determine the plan.
How doctors choose treatment after a recurrence
The interval from the last platinum dose to recurrence helps identify the treatment branch, but it is not the only factor. An oncologist also considers the cancer’s histology and grade, how it responded to prior treatment, previous exposure or intolerance to taxanes, bevacizumab or PARP inhibitors, symptoms, and the likelihood that a treatment will help relative to its side effects. A gynecologic oncologist should guide individual decisions.
As an Amazon Associate I earn from qualifying purchases.
The ASCO living guideline, version 2026.1.0, published June 8, 2026, addresses systemic treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, and primary peritoneal cancers. Recommendations for a particular patient may differ according to tumor type, local approvals, and clinical circumstances.
What does platinum-sensitive, resistant, or refractory mean?
These terms describe when the cancer returns or progresses in relation to platinum-based treatment. The National Cancer Institute’s PDQ describes recurrence more than six months after induction therapy as platinum-sensitive; recurrence within six months as platinum-resistant; and progression during induction therapy as platinum-refractory. The six-month interval is a treatment-planning category, not a guarantee about how an individual cancer will respond.
#1 Best Overall
- More than six months after platinum: Platinum-based retreatment is generally considered.
- Within six months: The cancer is generally considered platinum-resistant, and treatment usually shifts to non-platinum choices.
- Progression during platinum treatment: The cancer is considered platinum-refractory; the plan generally uses other approaches.
Can platinum chemotherapy be used again?
Often, yes, when the recurrence is platinum-sensitive and the patient is able to receive it. ASCO recommends offering a platinum combination rather than treating one specific combination as best for everyone. The options named in its 2026.1.0 guideline are:
| Combination | Medicines |
|---|---|
| Carboplatin plus PLD | Carboplatin and pegylated liposomal doxorubicin (PLD) |
| Carboplatin plus paclitaxel | Carboplatin and paclitaxel |
| Carboplatin plus gemcitabine | Carboplatin and gemcitabine |
Bevacizumab may be added to a platinum doublet. For a patient whose recurrent cancer responds to a bevacizumab-containing platinum regimen, maintenance bevacizumab is an option. The choice of regimen depends in part on previous treatments, prior response, likely adverse effects, other health conditions, and the patient’s goals; ASCO does not rank one of the three platinum doublets as universally superior.
Rank #2
What about PARP-inhibitor maintenance?
PARP-inhibitor maintenance after recurrent-disease treatment should not be assumed to be automatic. ASCO notes that the role of PARP inhibitors in second-line or later maintenance has changed in light of their use earlier in treatment, longer-term efficacy and safety evidence, and regulatory changes. The guideline calls for highly selective use. A clinician should check current local recommendations and product labeling for the specific situation.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →What if the cancer comes back within six months?
For platinum-resistant or platinum-refractory recurrence, ASCO lists several systemic treatment options. In high-grade disease, a validated positive FRα test can make mirvetuximab soravtansine an option. Other guideline choices include single-agent chemotherapy, chemotherapy combined with bevacizumab, and, conditionally, relacorilant with nab-paclitaxel.
Rank #3
| Option | How the guideline describes it |
|---|---|
| Mirvetuximab soravtansine | Strongly recommended for high-grade disease with validated FRα positivity. |
| PLD or paclitaxel | Recommended chemotherapy options; paclitaxel may be given weekly or every three weeks. |
| Bevacizumab with chemotherapy | A recommended option for eligible patients. |
| Relacorilant with nab-paclitaxel | A conditional option. |
| Gemcitabine alone | A conditional alternative. |
These are options to discuss, not a one-size-fits-all sequence. The treatment choice also depends on prior medicines, tolerability, symptoms and treatment goals.
When can mirvetuximab be used?
In the United States, the FDA indication for mirvetuximab soravtansine-gynx (Elahere) is for adults with FRα-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens. Selection must use an FDA-approved test. ASCO defines FRα positivity for this recommendation as at least 75% of tumor cells staining at intensity 2+ or 3+ by immunohistochemistry. Availability and approved use may differ outside the United States.
In the MIRASOL randomized trial of 453 patients in the indicated setting, median overall survival was 16.5 months with mirvetuximab and 12.7 months with investigator-choice chemotherapy. Median progression-free survival was 5.6 versus 4.0 months, and objective response was 42% versus 16%. These are results across the trial groups, not a forecast for an individual. The FDA prescribing information warns of ocular toxicity and also lists risks including pneumonitis and peripheral neuropathy; clinicians review safety monitoring and potential side effects when considering treatment.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Is surgery used for recurrent ovarian cancer?
Surgery is a case-specific discussion, not a routine step for every recurrence. ASCO finds insufficient evidence to recommend secondary cytoreductive surgery or hyperthermic intraperitoneal chemotherapy (HIPEC) routinely. For platinum-sensitive recurrence, clinicians may discuss secondary cytoreduction when they believe complete gross resection is highly achievable. Whether surgery is appropriate depends on the pattern of recurrence, the patient’s health, prior treatment and the likelihood of removing all visible disease.
Best Value
What else should be discussed?
Clinical trials
A clinical trial may be worth discussing, particularly when standard options are limited. Eligibility depends on the trial’s criteria and the patient’s prior treatment and health; an oncology team can identify whether a relevant study is available.
Follow-up after treatment
ASCO recommends individualized monitoring rather than one universal follow-up schedule. Depending on the situation, follow-up may include physical examinations, biochemical tests, imaging, and survivorship care.
How common is recurrence?
The National Cancer Institute’s PDQ, accessed October 3, 2026, reports that approximately 80% of patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer relapse after first-line platinum- and taxane-based chemotherapy. This population-level figure describes recurrence frequency; it does not determine which treatment will be appropriate for any one person.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
